从活血通络法探讨川芎嗪抗肝纤维化的作用机制研究进展

Research progress on the mechanism of ligustrazine in anti-liver fibrosis from the method of promoting blood circulation to remove meridian obstruction

肝纤维化是肝硬化发生的必经之路,属于早期阶段,具有可逆性。因此如何有效延缓持续进展,甚至逆转,是目前治疗肝纤维化关键性问题。中医认为其基本病机属于瘀血阻络,活血通络是基本治疗方法。综合国内外研究发现川芎嗪能通过调控多种细胞因子抑制肝星状细胞(HSCs)活化、诱导活化的HSCs凋亡、调控脂肪细胞因子、肝脏炎症反应、抗氧化应激、调节肝窦内皮细胞、自噬等发挥抗肝纤维化作用,在未来肝纤维化的治疗中具有应用前景。

Liver fibrosis is the only way for the occurrence of liver cirrhosis,which belongs to the early stage and is reversible.Therefore,how to effectively delay the sustained progress or even reverse is a key issue in the treatment of liver fibrosis at present.Traditional Chinese medicine believes that the basic pathogenesis belongs to blood stasis blocking meridians,and promoting blood circulation to remove meridian obstruction is basic treatment method.Comprehensive studies at home and abroad have found that ligustrazine can inhibit hepatic stellate cells(HSCs)activation by regulating a variety of cytokines,induce activated HSCs apoptosis,regulate adipocytokines,liver inflammation,anti-oxidant stress,regulate sinusoidal endothelial cells,autophagy and so on.It has a prospect in the treatment of liver fibrosis in the future.